List of Diagnostics Companies in Israel - 17

CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven using an AI Platform of computational disease models. With its extensive database of public and proprietary data, the company maps human diseases – tissue by tissue and cell by cell. Researchers of all levels rely on CytoReason’s technology to make data-driven decisions across the drug development life cycle. Scientists can identify potential targets, prioritize indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain valuable tools to manage and optimize entire drug portfolios.

DermaDetect is an AI driven software which enables remote diagnosis and treatment of skin disorders. Based on the latest technology, the system helps health care providers grow the efficiency of their workflow, profitability of their clinic while significantly improving patient care. Based on intelligent software, the platform integrates easily with existing systems, is easy to use, accessible 24/7 and has an attractive pay-per usage pricing model.

Founded in 2014, our company pioneered the first artificial pancreas technology. Since then, DreaMed has dedicated itself to developing decision-support tools in the diabetes management field. We are the world's first and only company to receive FDA clearance for a decision support system that utilizes data from CGM/SMBG (continuous glucose monitoring/self-monitoring of blood glucose) and insulin pumps. Our founders are all physicians and engineers. Our products are developed based on real insights from the clinical practice of diabetes specialists, physicians, and clinical researchers from the top diabetes centers worldwide. We prioritize privacy, security, quality, and regulatory compliance, operating under a stringent quality management system and adhering to ISO 27001, GDPR, and HIPAA standards. Additionally, our product FDA-cleared.

We designed a portable, affordable and easy to use hematology lab, which provides instant results like CBC, complete blood count. The platform technology houses multiple clinical applications and has an AI based microscope. It reduces cost, time and it improves the doctor-patient experience. EFA brings the LAB to the BLOOD and not the BLOOD to the LAB without the need for an expert preparation. EfA is changing the diagnostics paradigm step by step by enabling tests which were ONLY available in the labs/clinics/hospitals etc. to be done ANYTIME and EVERYWHERE. An early and rapid diagnostic is a key to the prevention of overuse and improper medications. Many millions of people cannot access a proper diagnostic due to their medical condition and/or where they live. Bringing as many as possible medical services closer to them, will make a huge impact on how we manage health around the world. The initial application of a complete blood count everywhere will give results in less than 5 minutes ON THE DEVICE. EfA also creates a marketplace for developers, partners and researches adding health-apps for various conditions and future diagnostic needs. EfA's RevDx portable device realtime analysis enables telemedicine applications.

HT BioImaging is a medical imaging company based in Tel Aviv, Israel, founded in 2015. The company specializes in innovative imaging technologies aimed at early cancer detection. Its main product is a patented medical imaging platform that uses Heat Diffusion Imaging (HDI) technology to create real-time images from heat diffusion in tissues. This platform is designed for immediate cancer detection at the point of care and in operating rooms. In addition to its primary focus on human healthcare, HT BioImaging has a subsidiary called HTVet, which applies its technology to the veterinary market. HTVet offers HT Vista, a non-invasive medical device that helps veterinarians rule out cancer in pets during clinical visits. The company serves hospitals and clinics, particularly in oncology and surgery, and is supported by a team of experts in various fields, including AI and thermodynamics.

By taking a simple blood test from the mother-to-be, we can read the fetal DNA! No more risky, complicated and late invasive tests like amniocentesis - we are revolutionizing the way prenatal testing is done.

IR-MED Inc. is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company's AI process to provide healthcare professionals with decision support in the detection and monitoring of various disease conditions. PressureSafe, the company's first product based on this platform, is a handheld device designed to revolutionize early detection of pressure injuries (PI) affecting skin and underlying tissue. Pressure Injury in the US alone accounts for $26.8B in healthcare spending and results in 60,000 deaths annually. PressureSafe is expected to contributes to early detection of pressure injuries, regardless of patient skin tone. This will drive equitable healthcare and help reduce the toll and cost of PI. IR-MED holds patents protecting its innovation in noninvasive tissue analysis, and in modeling and analysis of subcutaneous tissue.

At JaxBio, we are revolutionising the way cancer is diagnosed and managed by making cancer detection simpler, quicker, and more precise, and we're doing that through our innovative blood test technology. Our unique blood test offers advantages over traditional methods and traditional liquid biopsies. Based on its high sensitivity together with low cost and simplicity, we can deliver results faster with improved accuracy. By improving screening and early detection capabilities for cancer, healthcare providers and patients can now make better informed decisions sooner when time is of the essence. We use novel artificial intelligence (AI) algorithms to identify sets of biomarkers that are effective in detecting various types and subtypes of cancer at different stages. Our tests aren't just for initial diagnosis; they're also valuable tools for monitoring disease status and predicting how well a patient will respond to therapy. Our platform technology can also be used in a range of diseases, including various types of cancer, neurodegenerative diseases, and heart diseases. Connect with us to learn more.

MetaSight Diagnostics, a health technology company, is on a mission to create affordable and precise liquid biopsy diagnostics for early detection of a variety of chronic and acute diseases, utilizing proprietary, cost-effective mass spectrometry technologies (metabolomics, lipidomics and proteomics). The company has created the world’s largest and most comprehensive serum metabolomics dataset linked with Electronic Health Records and is pursuing additional omics. This unprecedented platform is used by MetaSight’s team of experts in analytical chemistry, AI, and medicine to develop and commercialize diagnostic products to improve human health.

Nanox AI is lighting up new pathways for smart population healthcare management with AI-based solutions, identifying patients at risk of having chronic disease and enabling the start of preventative care pathways. Integrated delivery networks and payers benefit from this technology with more accurate risk-adjustment, timely intervention, and improved quality of health services, while significantly reducing the associated costs. Nanox AI enables better, fairly reimbursed population health management and wellbeing for larger patient populations. #population health #AI #machine learning #digitalhealth #medicalimaging

NeuroKaire is a precision psychiatry and neurology company using a cutting-edge combination of stem-cell technology, genomics, and AI for treatment optimization and effective drug development. NeuroKaire uses this innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients. Leveraging NGS-based and PCR-based technology to identify methylation changes, the Company's pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The Company's non-invasive EpiCheck® delivers highly accurate and sensitive results, all while providing a seamless testing option for physicians, patients, and the healthcare system. The Company is building an EpiCheck® franchise, beginning with the Bladder EpiCheck® kit, CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer, and FDA 510(k) cleared for bladder cancer recurrence in the United States. The Company is advancing its Lung EpiCheck® test towards commercialization for high-risk individuals while evaluating additional tests for other high-risk diseases.

OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. OncoHost’s proprietary platform, PROphet®, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphet® NSCLC test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage.

Pronto Diagnostics is a leading provider of molecular diagnostic products and services, with extensive knowledge, experience and R&D capabilities in genetic analysis. ProntoLab™, Pronto's molecular services laboratory, has accreditation from the Israel Ministry of Health and ISO 9001:2008 certification. It provides both clinical diagnostics and clinical research services, which include DNA purification; sequencing and deletion/duplication analysis for any gene; fragment analysis; pharmacogenetic testing and epigenetic tests. ProntoLab™ carries out sequencing and data analysis of whole-exome, as well targeted gene panels for specific diseases and syndromes. Pronto Diagnostics has been granted exclusive distribution rights in Israel from leading international molecular diagnostic companies to high quality products and technologies. We are cooperating with the best and most advanced labs in the world such as Centogene, TheragenEtex, Sequenom, MRC-Holland, 10x Genomics, Multiplicom-Agilent, Sophia genetics, DNA Genotek and many more. Pronto Diagnostics provides highly professional technical support. Its product specialists are dedicated to supporting the company's customers wherever they may be. For more details please contact our office at : info@prontodiagnostics.com

Salignostics is an R&D company focusing on the development of saliva based rapid diagnostics tests (RDT), utilizing a lateral flow immunoassay platform. The company's platform is comprised of a "tool box"​ of technologies which amplify the saliva as a detectable body-fluid by overcoming different chemical and biological saliva related obstacles. Implementation of these technologies transforms saliva from a non-detectable to a detectable body-fluid

Senseera's GEM (Genomic Expression Maps) BIOMARKERS, is a novel biomarker discovery platform based on a patent protected chromatin epigenomics (cfChIP-seq) liquid biopsy technology (Sadeh, Nature Biotechnology, 2021). GEM BIOMARKERS turns a simple blood draw into unparalleled, quantitative, cell-specific gene expression, and regulation data from cell-free DNA. Going beyond traditional methods like cfDNA genomics and methylation, it offers a transformative layer of data for various applications including biomarker discovery, tissue-agnostic MRD detection, response to therapy, dose optimization, disease subtyping and more. Backed by a database of over 20,000 annotated disease samples and a 2,000+ healthy subjects cohort, Senseera is collaborating with leading drug developers from big pharma and biotechs, to deliver mechanistic insights with exceptional sensitivity and specificity across multiple indications, advancing human health and precision medicine worldwide.

TechnoPulm introduces a disruptive diagnostic tool for Pulmonary-Function Testing (PFT) in patients suffering from respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, covid related ailments and others. TechnoPulm is the only company that has systems that allows ALL lung function diagnostic tests to be performed from the doctor's office and the patient's home by using a small handheld device connected to a comprehensive tool to enable a remote healthcare solution. TechnoPulm enables patients to interact with their physician from anywhere at any time.